Myovant Sciences Ltd (MYOV) Research Coverage Started at Evercore ISI
Evercore ISI initiated coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a note issued to investors on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock.
Separately, Zacks Investment Research cut shares of Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $18.20.
Shares of Myovant Sciences (MYOV) traded down 6.32% during mid-day trading on Wednesday, reaching $9.93. The company had a trading volume of 94,715 shares. The company’s market capitalization is $598.58 million. The company’s 50-day moving average price is $11.28 and its 200-day moving average price is $11.80. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $15.50.
Large investors have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP raised its position in Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after buying an additional 3,971 shares during the period. Bank of New York Mellon Corp raised its position in Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares during the period. Wells Fargo & Company MN raised its position in Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in Myovant Sciences during the second quarter valued at about $165,000. Finally, BB Biotech AG raised its position in Myovant Sciences by 0.4% in the second quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock valued at $38,811,000 after buying an additional 14,336 shares during the period.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.